- Combination Drugs
- Acid Blockers
Chronic Cough Market was valued at USD 6723 million in 2022 and is poised to grow at a CAGR of 8% over 2023-2029. A chronic cough is a cough that lasts eight weeks or longer, and the most common causes include tobacco use, postnasal drip, asthma, and acid reflux. Based on the drug class, the combination drugs segment is anticipated to dominate the market share over the forecast period. According to the report from several studies, the worldwide prevalence of chronic cough was estimated as 9.6%, whereas the incidence rate ranged from 1.16 to 5.70 per 100 person-years. The rising prevalence of chronic cough and increased global healthcare expenditure will act as the chronic cough market growth drivers. However, the high cost of treatment would be the lagging factor for the market. The development of novel technologies for diagnosis and novel drug development to treat chronic cough are opportunities for pharmaceutical companies for market expansion.
Fastest Growing Market
The various initiatives from pharmaceutical companies and governments towards launching more drugs for chronic cough will be major factors for the chronic cough market expansion. For example, Nocion Therapeutics conducted a phase-I trial for cough in the USA for NOC 100. Whereas lack of training for healthcare professionals and product recalls could be the restraining factor for the market. For instance, in June 2020, GSK had to recall “Children’s Robitussin Honey Cough and Chest Congestion DM” and “Children’s Dimetapp Cold and Cough” due to “incorrect dosage cups”. Thus, the increased awareness, research, and development for chronic respiratory disorders will lead to the growth of the market within the forecast period.
The Chronic Cough market was valued at USD 6723 million in 2022 and is expected to grow at a 8% CAGR over the forecast period 2023 – 2029.
The development of novel technologies for diagnosis and novel drug development to treat chronic cough are the key opportunities for the Chronic Cough market.
The rising prevalence of chronic cough and increased global healthcare expenditure are the growth drivers in the Chronic Cough market.
Merck KGaA, Novartis AG, Johnson & Johnson Private Limited, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Biocon, Bristol-Myers Squibb Company, and GSK plc. are a few companies operating in the Chronic Cough market.